Lecturers
ISOBM2022 Lecturers
(the list of lecturers is preliminary at the moment)
Lecturers
| Lecturer | Title of Lecture |
|---|---|
| Barak Vivian | sIL-2R- an important Immuno- Biomarker for Cancer |
| Bendas Gerd | Heparin in Oncology – Novel Targets and Activities for an Immuno-Oncological Perspective |
| Blatnik Ana | Genetic analysis of archival tissue when testing for hederitary cancer predispositions |
| Boltežar Gašper | The role of tumor markers in cystic lesions of the pancreas |
| Bombač Alenka | Mutational spectrum in patients with metastatic gastrointestinal stromal tumours treated at Institute of Oncology Ljubljana |
| Bronkhorst Abel Jacobus | Understanding biology of cell-free nucleic acids for clinical decision making |
| Chechlinska Magdalena | Molecular profiling of ovarian tumor microenvironment |
| Colas Ortega Eva | Use of biomarkers in diagnosis and presurgical patient stratification |
| Danesi Romano | Clinical implementation of pharmacogenetics to reduce the risk of toxicity of anticancer drugs |
| Datar V | New Dynamics in Cancer Outcomes: Encyclopaedic Tumour Analysis |
| Dragoš Štajerčič Vita | The use of RNAseq in discovery of splicing abnormalities |
| Duffy Michael | Personalised treatment for cancer: biomarkers are showing the way |
| Ecke Thorsten | BTA stat, NMP22, UBC rapid test, UBC rapid visual, and uromonitor as tumour marker for urinary bladder cancer: interim results of a german multicentre-study |
| Ferrari Paola | Inhibiting immunosuppression immunotherapy in solid tumors |
| Fishmann Dmytro | Machine learning in medicine |
| Francesco Fanfani | Implementing the TCGA classification endometrial cancer: consequences on medical and surgical approaches |
| Garrido Manuel Antonio | Multi-biomarker evaluation in prostate cancer patients with PSA between 2 and 10 ng/mL |
| Haselmann Verena | Implementation of liquid biopsy into patient care |
| Heitzer Ellen | New developments in liquid biopsy diagnostics |
| Holdenrieder Stefan | Current use of protein and molecular markers in guidance of lung cancer patients |
| Holdenrieder Stefan | Proteomic and metabolomics multimarker approaches for lung cancer |
| Holdenrieder Stefan | Nucleosomes and Exosomes as sources for biomarkers |
| Kagan Jakob | Validation Studies of Biomarkers for Early Detection of Aggressive Prostate Cancer |
| Karlikova Marie | Importance of Matrix metalloproteinases in tumour diseases |
| Kinkorova Judita | Biobanking and big data |
| Kloft Charlote | ONTARGET – TDM to optimize oral anticancer targeted therapy |
| Krajc Mateja | Cancer genetic screening and personalised cancer risk assessment |
| Kučera Radek | The importance of PHI for the prediction of surgical solution or active surveillance of prostate cancer patients |
| Lainšček Duško | An enhanced CRISPR based tool for treating chronic myelogenous leukaemia |
| Lanišnik Rižner Tea | AKR1C and AKR1B enzymes as biomarker candidates of endometrial and ovarian cancers |
| Lanišnik Rižner Tea | BioEndoCar: Biomarkers for diagnosis and prognosis of endometrial carcinoma |
| Liszcova Libuše | Genetic biomarkers in the diagnosis of diffuse gliomas |
| Looijenga Leendert | Human germ cell tumours; clinical implementation of laboratory findings |
| Marc Janja | Biomarkers in bone metastasis |
| Marta Sanchez-Carbayo | Multiplexed -omics profiling for bladder Cancer diagnostics |
| Marta Sanchez-Carbayo | Methylation profiles for bladder Cancer diagnostics |
| Marzia Del Re | The application of liquid biopsy to cancer treatment monitoring |
| Michael van den Heuvel | Clinical needs for useful application of tumor markers |
| Mirza Muhammad Faran Ashraf | DNA Nanotechnology for Modulating the Growth and Development of Neurons |
| Mlinarič Raščan Irena | Molecular signatures of venetoclay chronic lymphocytic leukaemia resitence |
| Muley Thomas | Use of tumor marker classificators for post-surgery stratification of patients with early lung cancer |
| Nicolini Andrea | A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone |
| Oehr Peter | A new diagnostic approach for a more realistic tumor marker follow up during therapy |
| Oehr Peter | New established types of ROC-curves and their clinical impact |
| Podgornik Helena | Diagnostic algorithms ensure recognition of Ph-like acute lymphoblastic leukemia molecular markers |
| Reijnen Casper | Integrating biomarkers into ENDORISK prediction model |
| Ritter Christoph | Translational Platform for Anticancer Treatment Strategies |
| Romano Andrea | ENITEC Presentation |
| Schröder Lea | Immunogenic cell death markers in ovarian cancer |
| Schroeder Christoph | Affinity proteomics for the discovery of novel biomarkers and therapeutic targets |
| Sever Matjaž | Clinical implication of CART therapy |
| Smrkolj Tomaž | Biomarkers in urology |
| Strojnik Andrej | Germline genetic testing for cancer treatment in prostate and pancreatic cancer patients |
| Škerl Petra | Methylation status of mismatch repair genes in endometrial and colorectal cancer |
| Škof Erik | Clinical importance of BRCA mutation in ovarian cancer |
| Šmid Lojze | Chromogranin in the diagnostic and therapy of neuroendocrine tumors |
| Tokarz Janina | Metabolomics for deep phenotyping in frequent human diseases |
| Topolčan Ondrej | Significance tumour biomarkers for tumour aggressiveness |
| Treves Abraham | Gut microbiome and fecal transplantation in Cancer treatment |
| Turnšek Nina | Oncogenic driver ALK fusion in NSCLC with case report |
| Uhlig Carsten | Artificial intelligence approaches for tumor marker evaluations |
| Unk Mojca | (R)Evolution of non-small cell lung cancer systemic treatment |
| van Rossum Huub | Continued need for harmonization of tumor marker assays |
| van Rossum Huub | Laboratory needs for reliable application of tumor markers |
| Viehbaum L | Inter-assay comparison of tumor markers in an EQA setting |
| Wojtaewicz Nathalie | Longitudinal variation of tumor markers assays in an EQA setting |
| Wolf Dominik | Risk prediction for GvHD in patients with AML after stem cell transplantation |
| Zadnik Vesna | Public health interventions for reducing cancer burden and improving cancer care: national clinical registries and organised screening programmes |